Prospective, multicenter study of ventricular assist device infections

Rachel J. Gordon, Alan D. Weinberg, Francis D. Pagani, Mark S. Slaughter, Pat S. Pappas, Yoshifumi Naka, Daniel J. Goldstein, Walter P. Dembitsky, Julie C. Giacalone, Jennifer Ferrante, Deborah D. Ascheim, Alan J. Moskowitz, Eric A. Rose, Annetine C. Gelijns, Franklin D. Lowy

Research output: Contribution to journalArticle

129 Scopus citations

Abstract

Background-Ventricular assist devices (VADs) improve survival and quality of life in patients with advanced heart failure, but their use is frequently complicated by infection. There are limited data on the microbiology and epidemiology of these infections. Methods and Results-One hundred fifty patients scheduled for VAD implantation were enrolled (2006-2008) at 11 US cardiac centers and followed prospectively until transplantation, explantation for recovery, death, or for 1 year. Eightysix patients (57%) received HeartMate II devices. Data were collected on potential preoperative, intraoperative, and postoperative risk factors for infection. Clinical, laboratory, and microbiological data were collected for suspected infections and evaluated by an infectious diseases specialist. Thirty-three patients (22%) developed 34 VAD-related infections with an incidence rate of 0.10 per 100 person-days (95% confidence interval, 0.073-0.142). The median time to infection was 68 days. The driveline was the most commonly infected site (n=28); 18 (64%) were associated with invasive disease. Staphylococci were the most common pathogen (47%), but pseudomonas or other Gram-negative bacteria caused 32% of infections. A history of depression and elevated baseline serum creatinine were independent predictors of VAD infection (adjusted hazard ratio=2.8 [P=0.007] and 1.7 [P=0.023], respectively). The HeartMate II was not associated with a decreased risk of infection. VAD infection increased 1-year mortality (adjusted hazard ratio=5.6; P<0.0001). Conclusions-This prospective, multicenter study demonstrates that infection frequently complicates VAD placement and is a continuing problem despite the use of newer, smaller devices. Depression and renal dysfunction may increase the risk of VAD infection. VAD infection is a serious consequence because it adversely affects patient survival. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01471795. (Circulation. 2013;127:691-702.).

Original languageEnglish (US)
Pages (from-to)691-702
Number of pages12
JournalCirculation
Volume127
Issue number6
DOIs
StatePublished - Feb 12 2013

    Fingerprint

Keywords

  • Depression
  • Heart failure
  • Heart-assist devices
  • Infection
  • Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Gordon, R. J., Weinberg, A. D., Pagani, F. D., Slaughter, M. S., Pappas, P. S., Naka, Y., Goldstein, D. J., Dembitsky, W. P., Giacalone, J. C., Ferrante, J., Ascheim, D. D., Moskowitz, A. J., Rose, E. A., Gelijns, A. C., & Lowy, F. D. (2013). Prospective, multicenter study of ventricular assist device infections. Circulation, 127(6), 691-702. https://doi.org/10.1161/CIRCULATIONAHA.112.128132